This week, the World Health Organization issued its first guidance on GLP-1 medications for adults with obesity, recommending long-term, continuous use when clinically appropriate.
In early November, President Donald Trump penned a deal with drug manufacturers Eli Lilly and Novo Nordisk that would decrease the price of popular GLP-1 weight-loss drugs for patients on Medicare and Medicaid, as well as cash buyers.
As many private insurers are declining to cover these medications, will the deal make a difference for the obesity rate?
On Cincinnati Edition, we talk about what expanded coverage might mean for Americans.
Guests:
- Malti Vij, MD, adjunct assistant professor, Department of Internal Medicine, University of Cincinnati
- Dave Knapp, founder, On the Pen
Ways to listen to this show:
- Tune in live at noon ET M-F. Call 513-419-7100 or email talk@wvxu.org to have your voice heard on today’s topic.
- Catch the replay on 91.7 WVXU and 88.5 WMUB at 8 p.m. ET M-F.
- Listen on-demand. Audio for this segment will be uploaded to this page by 4 p.m. ET., or subscribe to our podcast.